Broadening Horizons: HER2-Directed Antibody-Drug Conjugates in the Realm of HER2-Expressing Solid Tumors, including Gynecological, Bladder, and Biliary tract Cancers

Since this activity was originally posted online, the FDA granted accelerated approval for use of trastuzumab deruxtecan to treat adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. For more information about this approval, please visit the FDA website:


Antonio González-Martín, MD, PhD
Director, Cancer Center Clínica Universidad de Navarra
Director of the Department of Medical Oncology
Specialist in Medical Oncology
Madrid, Spain


This enduring activity will help you evaluate emerging biomarker-driven, tumor-agnostic approaches toward the management of hard-to-treat, advanced solid tumors that express HER2, including cancers of the endometrium, ovary, cervix, bladder, and biliary tract. This activity will review findings from clinical investigations of HER2-directed therapy to treat these tumors, offer practical guidance on multidisciplinary monitoring and management of treatment-related adverse events in patients receiving a HER2-directed therapy; and provide expert perspectives on the role biomarkers play in this strategy. This interactive program combines didactic instruction with case-based discussions and animations.


This activity is intended for U.S.-based community oncologists involved in the treatment of patients with HER2-positive solid tumors including gynecological, bladder, and biliary tract cancers.


Upon the completion of this program, attendees should be able to:

  • Analyze findings from clinical investigations regarding the effectiveness, safety, and patient tolerance of novel HER2-directed ADCs in managing solid tumors with HER2 overexpression
  • Assess adverse events linked to the administration of HER2-directed ADCs
  • Evaluate the available data on prospective predictive biomarkers for HER2-directed ADCs for HER2-expressing solid tumors


In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


Speaker Relationships Manufacturer
Antonio González-Martín MD Consultant Alkermes, Amgen, AstraZeneca, Clovis, Genmab, GlaxoSmithKline, HederaDx, Immunogen, Kartos, Karyopharm, Illumina, Mersana Therapeutics, MSD, Novartis, Novocure, Oncoinvent, PharmaMar, Roche, SOTIO Biotech, SUTRO Biopharma, Seagen, Takeda Pharmaceuticals, and Tubulis
Contracted Research GlaxoSmithKline, Roche Instituto de Salud Carlos iii, and AECC Pharmaceuticals
Speakers Bureau AstraZeneca, Clovis, GlaxoSmithKline, Immunogen, Mersana Therapeutics, MSD, Novocure, PharmaMar, Roche, and Takeda Pharmaceuticals

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and a nurse practitioner.

Individuals in Control of the Content of the Activity

The individuals in control of the content of the activity reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Shannon Mutch MS, RN, OCN, has nothing to disclose.
  • M. Susan Burke, MD, has nothing to disclose.
  • A medical reviewer from CME Peer Review LLC, has nothing to disclose.
  • Kim L. Farina, Medical Director for Med Learning Group, has nothing to disclose.
  • Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
  • Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.


Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.


Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at


Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASED DATE: March 05, 2024
EXPIRATION DATE: March 05, 2025

Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

Healthcare Business Review Award

We are thrilled to announce that we have been recognized as one of the Top 10 Health Education Services Providers by Healthcare Business Review!

This award is both an honor and a testament to our cumulative dedication to providing the best continuing medical education (CME) services to HCPs across the globe. We are proud to be part of this distinguished group and look forward to continuing to have MLG be one of the best CME providers in the country.

Thank you to Healthcare Business Review for this recognition and for shining a light on the importance of accurate and accessible healthcare education.

#TopHealthEducationProvider #MedLearningGroup #HealthcareBusinessReview #MedicalEducation

Best of America Small Business Awards
Best Website

The Best of America Small Business Website award recognizes the best website launched by a small business since 2021. Technology is a key growth enabler for small businesses. The best in tech track recognizes small businesses as experts in technology and innovation from innovators, app developers, and website creators. Visit our award-winning Ophthalmology and Optometry web portal:

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.